ArticleDiscover oncology2025
Identification of MFSD3 as a potential prognostic biomarker of cervical cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundCervical cancer (CC) is a common malignant tumor of the female reproductive system. Currently, patients with advanced or recurrent CC have poor prognosis. The aim of this investigation is to pinpoint key genes that might influence the prognosis of CC patients.
methodsCC-related datasets were obtained from TCGA and GEO databases. We employed differential expression analysis and univariate Cox regression to identify the genes associated with CC prognosis. The prognostic value of hub gene MFSD3 was then evaluated via Kaplan-Meier survival curve and multivariate Cox regression analyses. Functional analysis and immune cell infiltration analysis were then conducted. Finally, the promising targeted drug was predicted and analyzed through molecular docking.
resultsCompared to normal cervical samples, MFSD3 was significantly upregulated in CC samples. The elevated levels of MFSD3 were linked to a poor prognosis and was an independent prognostic biomarker for CC. Functional enrichment analysis showed that MFSD3 was involved in certain energy metabolism related signaling pathways. Immune cell infiltration results showed that high MFSD3 expression was associated with infiltration of various immune cells, such as M2 macrophages. The results of molecular docking, molecular dynamics simulation and cellular thermal shift assays showed that two anticancer drugs (Palbociclib and Dabrafenib) can stably bind to the MFSD3 protein.
conclusionOur study revealed that MFSD3 may serve as a potential prognostic biomarker for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.